Today Stories

Test is available through physicians for use with patients being evaluated for possible Alzheimer's disease or other causes of cognitive impairment Labcorp is the first company to deliver a blood-based Amyloid-Tau-Neurodegeneration (ATN) Profile, which uses a trio of blood biomarkers to detect the hallmarks of Alzheimer's disease BURLINGTON, N.C., Oct. 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease – amyloid plaques, tau tangles and neurodegeneration (ATN) – which can help accelerate the path to diagno…

Partnership with HealthyWomen and actor, mother and business owner Nicole Ari Parker encourages people to get informed about the importance of COVID vaccination and vaccine options  The Choose to Protect survey, conducted by The Harris Poll, found 85% of U.S. adults aged 45+ agree it is important to have a range of COVID vaccine options for themselves and their family1 Only two in five survey respondents say they are highly knowledgeable about the science behind different types of COVID vaccines1 GAITHERSBURG, Md., Oct. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it has joined forces with HealthyWomen and actor, mother and business owner Nicole Ari Parker to launch Choose to Pr…

2024 marks the 38th year of the PM Society Awards which celebrate creativity, impact, and innovation in pharma and healthcare communications. We are delighted that Twist Health will be our headline sponsor for the second year running. We are pleased to announce that the awards are now open for entry! This year’s categories are: Product Promotion (Single Piece) Product Brand Campaign Best Promotional Campaign for a Company or Initiative Charity or Patient Organisation including Pro-Bono Internal Communications Best Creative Medical Education Programme or Campaign Meetings, Events and Exhibitions Disease Awareness: Public/Patients (including Film and Animation) Disease Awareness: HCPs (including Film and Animation) Patient Support Agency Self Promotion and Internal Communication Best Use of…

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati’s Promising Pipeline Includes a Potent Selective PRMT5/MTA Inhibitor, MRTX1719, a Potential First-in-Class and Best-in-Class Asset; and Early Clinical Pipeline Feature…

Increased capability to produce medicines for challenging diseases including cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders. Thermo Fisher made a significant investment since 2021 to add 58,000 square feet of biologics manufacturing space. The addition was facilitated by state and local tax incentives, including a 10-year new project abatement beginning in 2024. The company employs more than 1,000 people in the state of Missouri and more than 900 work at the site. “We’re providing our customers with greater flexibility to scale manufacturing and better serve patient…

Labcorp to acquire Baystate Health's outreach laboratory business and select operating assets Collaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts BURLINGTON, N.C., Oct. 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing. In addition, Labcorp will…

Girls Inc. alumnae in New York, San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges A social media campaign shares authentic stories and aspirations of girls entering the workforce IRVINE, Calif., Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women's trajectories through college and career entry. The Allergan Aesthetics effort will focus specifically on leadership paths in STEM (science, technology, engineering, and ma…

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--AirLife, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as SunMed, today announced the completion of its acquisition of Avanos Medical, Inc.’s (NYSE: AVNS) (“Avanos”) respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. The acquisition adds three complementary brands, the R&D expertise behind them and two manufacturing facilities into AirLife’s growing platform. The transaction advances AirLife’s strategy to enhance its leading portfolio of the most trusted products in anesthesia and respiratory care and serve even more customers as a one-stop source for the highest-quality consumable breathing solutions that support the…

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma NORTH CHICAGO, Ill., Sept. 29, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. Data did not demonstrate…

Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB). Macomics’ operations are located in Edinburgh and Cambridge, two major hubs of life science research in the UK with R&D teams split 50:50 across both sites. To accommodate expansion and to be co-located in an entrepreneurial centre of scientific excellence, Macomic…

The 8-week programme offers in person training from industry leaders to build strong business foundations and prepare for investment  Finalists have the chance to win a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures  The winner will be announced at the GIANT Health conference on 5th December 2023  Sandwich, UK, 27th September 2023 / Sciad Newswire / Discovery Park / Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a busine…

94% of Advanced Practice Providers (APPs) believe more educational resources about the rare blood cancer multiple myeloma could help improve the patient experience HORSHAM, Pa., September 26, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with the Advanced Practitioner Society for Hematology and Oncology (APSHO), today announced the launch of Make It HAPPen™, a multi-year effort designed to recognize and support Advanced Practice Providers (APPs) in the life-changing care they provide to people living with multiple myeloma. The campaign launched in response to a recent national survey, which showed that, among people who are living with multiple myeloma, most (93%) viewed APPs as essential to their care, and more than half (61%) felt they could ask t…

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss. The most advanced clinical-stage candidate is DB-OTO, which is currently being studied in the global Phase 1/2 CHORDTM clinical trial, and is an investigational cell-selective, adeno-associated virus (AAV) gene therapy designed to provide durable, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of…

Castres, France and Cambridge UK, 25 September 2023 – Pierre Fabre Laboratories and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to identify pre-clinical candidates against multiple oncology targets. Under the terms of the agreement, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of targets and use fragment and structure-based methods to identify small molecules that modulate their activity. This research will be combined with the oncology experience of Pierre Fabre Laboratories to identify drug candidates for treatment of a range of cancers for further development and commercialisation by Pierre Fabre Laboratories.  The research at Vernalis will be funded by Pierre F…

Breakthrough Expands its International Footprint, Entering the Burgeoning Amsterdam Life Science Community in Partnership with the Amsterdam University Medical Center Anticipated to be One of the World's Most Advanced and Sustainable Laboratory Environments, Kavel F by Breakthrough Aims to Achieve Carbon Negative Operations and a BREEAM Outstanding Rating AMSTERDAM, Sept. 21, 2023 /PRNewswire/ -- Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions. Neogene Therapeutics (Neogene), a wholly owned subsidiary of global biopharmaceutical c…

Solution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards Dublin, Ireland – 20 September 2023 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to…

Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, several of the Pfizer employees associated with the portfolio will join Alexion as employees. Financial considerations Alexion has purchased and licenced the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales. Notes Alexion Alexion, AstraZeneca Rare Disease, is the group within AstraZ…

Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change Paris, September 19, 2023 – As global leaders gather at the United Nations’ 78th General Assembly, Sanofi is delivering vital support to communities beset by climate turbulence and by unmet medical needs. These critical initiatives come as the global healthcare company confirms its commitment to positively impact society by tackling climate change and its consequences for human health. Ramping up adaptation efforts and initiatives to address the impact of climate change on the health of vulnerable communities becomes increasingly critical. Through Foundation S, Sanofi’s philanthropic organization, the company is strengthening locally led adaptation and health resilience programs…

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide New Brunswick, N.J., Sept. 14, 2023 – For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare innovation and tackling the toughest health challenges, the Company is updating its brand and uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare. The announcement marks the next era for Johnson & Johnson, which is leveraging its expertise in innovative medicine and medical tech…

Takeda’s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion (Approx. USD 167.5 million) Since Program Inception in 2016. More Than 24,500 Takeda Employees Worldwide Participated in the Selection of the Five New Partnerships: Society for Family Health Rwanda, Relief International, Mercy Corps, University of Nairobi and Partners In Health. With This New Cohort of Partnerships, Takeda’s Global CSR Program Expects to Reach 25.2 Million People in 92 Countries by 2028. OSAKA, Japan and CAMBRIDGE, Massachusetts, September 13, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced five new partnerships to its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in low- and middle-income countries. The new part…